European Psychiatry - Volume 33 - March 2016

686 / 812

S682 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
comorbid medical conditions, it can severely influence the desir-
able outcome.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1041
Subacute psychiatric hospitalization
unit: The role of clozapine
O. Orejas ∗ asferrer Herrera , C. Macías Castellví ,
P. Flores Martínez
Neuropsychiatry and Addictions Institute INAD, Parc de salut Mar,
Psychiatry Hospitalization, Barcelona, Spain
∗ Corresponding author.
Introduction Several studies report that Clozapine is more effec-
tive in reducing symptoms of schizophrenia, producing clinically
meaningful improvements and postponing relapse than other
antipsychotic strategies.
Objectives To analyze the prescription of Clozapine in a sample
of 88 inpatients admitted to a subacute psychiatric hospitalization
unit.
Methods This is a transversal study. All patients admitted
for a medium-term psychiatric treatment since 01/06/2014 to
30/11/2015 were included. Data about socio-demographical status
and clinical situation were obtained and compiled in a database.
This study compares patients receiving clozapine treatment with
thosewho receive other psychopharmacologic treatment. Statistics
were performed using SPSS Software.
Results Eighty-eight patients (52% men; mean age: 48.6 years)
composed the sample. In 58% of cases, schizophrenia and schizoaf-
fective disorder were the diagnoses motivating the admission.
Within the 51 patients with Schizophrenia o Schizoaffective Dis-
order, 16 of them (31.4%) received Clozapine. Comparing clozapine
group vs non-clozapine group, therewere no significant differences
between the groups in terms of sex, civil state or working state.
Instead, Clozapine group patients were older, had a major number
of previous hospitalization admissions and had a larger trajectory
of their disorder.
Conclusions Patients requiring treatment with Clozapine had a
major number of hospital admissions and had more often com-
mitted suicide attempts, suggesting a more severe course of the
disorder. They were older than the non-clozapine group. Clozap-
ine is delayed in its use among resistant-treatment patients. It is
worth highlighting that only 16 cases of Schizophrenia inpatients
received Clozapina. It could mean that Clozapine is underpre-
scribed.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1042
The treatment of autism with
pipamperone: A case report
B. Petrosino ∗ . Signorelli agnano di San Lio
C. Petrosino guglia
1 Psichiatria, Medicina clinica e sperimentale, Caltagirone, Italy
2 Psichiatria, Medicina Clinica e sperimentale, Catania, Italy
3 Psichiatria, ASP Catania, Caltagirone, Italy
∗ Corresponding author.
Introduction Adults with autism spectrum disorders (ASD) often
have behavioral disorders, like aggression, agitation and self-injury.
These problems are frequently severe enough to limit educational
and developmental progress. Only risperidone and aripiprazole
have so far been approved by the FDA for the treatment of behav-
ioral disturbance associated with autism. These drugs are not
very effective in the long term, with little benefits to the social
functioning and they are associated with side effects. This case
report describes the use of pipamperone, in treating behavioral
disorders of a patient with autism spectrum disorder and severe
mental retardation.
Case presentation Here is presented the case of a 32-year-old
man with autism spectrum disorder, severe mental retarda-
tion (caused by undiagnosed phenylketonuria for the first 3
years of life) treated with antipsychotics since childhood. He
showed numerous episodes of psychomotor agitation, hetero-
direct physical aggression and self-injury, andmovement disorders
induced by drugs. Treatmentwithpipamperone reduced drastically
crises of psychomotor agitation, and behavioral disorders, without
extrapyramidal side effects, and led to an improvement in social
functioning. The control of behavioral symptoms associated with
adherence to treatment was maintained for 6-month follow up.
These clinical observations are supported by ratings using: ABC,
CGI-S and CGI-I, VABS, SAS, AIMS.
Conclusion This case report provides the first potential evidence
that pipamperone may be effective in treating behavioral prob-
lems associated with autism spectrum disorders. Moreover, the
improvement of social functioning and the lack of extrapyrami-
dal side effects make this drug notable for its effectiveness and
tolerability.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1043
Effect of metformin treatment on
metabolic parameters in atypical
antipsychotic-treated schizophrenic
patients
V. Prisco ∗, S. Sorice , F. Franza , M. Fabrazzo
1 University of Naples SUN, Department of Psychiatry, Naples, Italy
2 Neuropsychiatric nursing home “Villa dei pini”, Avellino,
Department of Neuropsychiatry, Avellino, Italy
∗ Corresponding author.
Few studies have compared the effect of Metformin treat-
ment on metabolic parameters in atypical antipsychotic-treated
schizophrenic patients. The present study examined metabolic
abnormalities due to clozapine or olanzapine in schizophrenic
patients and, secondly, the effect of metformin treatment on these
parameters. Twenty-six patients (19 M and 7 F) from neuropsy-
chiatric nursing home “Villa dei pini” (Avellino) were enrolled,
in collaboration with our Department of Psychiatry, University of
Naples SUN. All patients had been diagnosed according to DSM-IV
criteria. They were recruited from July 2013 to January 2015. Cloza-
pine or olanzapine-related hyperglycemia required metformin
introduction in therapy. All prescribed drugs were maintained
at the same therapeutic daily dose during our study. We per-
formed 1, 3 and 6 months follow up after metformin initiation. For
each patient fasting cholesterol, glucose, triglycerides, body weight
(BW), body mass index (BMI), systolic and diastolic blood pressure
(BP) were evaluated. SPSS 16.0 (Statistical Package for Social Sci-
ence) was used for data analysis. After antipsychotic treatment
BMI, fasting glucose and triglycerides were significantly higher
respect to basal values (P < 0.01, P< 0.0001, P < 0.05, respectively).
After metformin treatment, a significant improvement in fasting
glucose, cholesterol and triglycerides was registered (P < 0.001).
Conversely, BMI values, althoughnot significant (P< 0.168), showed
a trend in increasing. This observational study underlines that
metformin in antipsychotic-treated patients could be useful in pre-
venting clozapine or olanzapine related metabolic abnormalities in
schizophrenic patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.